Abstract |
We studied clinical effects of ceftazidime (CAZ) alone or in combination with aspoxicillin (ASPC) against various infections in obstetric and gynecological patients. 1. Obstetric and gynecological patients (n = 91) with various infectious diseases were treated with CAZ alone (1-2 g x 2/day, n = 54) or in combination with ASPC (1-2 g x 2/day, n = 37) administered via drip infusion. 2. CAZ alone or in combination with ASPC was efficacious in 50 out of 54 (92.6%) or 33 out of 36 (91.7%) patients, respectively. Overall, the efficacy ratios were 46/49 (93.9%) against gynecological infections, 21/25 (84.0%) against perinatal infections and 16/16 (100%) against other infections. The bacteriological efficacy ratio was 21/21 (100%) while clinical effectiveness in cases in which causative agents were known was observed in 20 out of 21 (95.2%) patients. In patients who had not respond to other treatments, CAZ alone, and in combination with ASPC were effective in 15 out of 16 (93.8%) and 6 out of 8 (75.0%) patients, respectively, hence the overall efficacy ratio was 21/24 (87.5%). 3. Abnormal values in clinical laboratory tests were obtained in 3 out of 91 (3.3%) patients. No other adverse side effects were observed in any of the patients.
|
Authors | T Chimura, T Hirayama, T Funayama, N Nara, R Miyata, H Kanasugi, S Sato, T Oda, N Saito, N Morisaki |
Journal | The Japanese journal of antibiotics
(Jpn J Antibiot)
Vol. 46
Issue 9
Pg. 827-35
(Sep 1993)
ISSN: 0368-2781 [Print] Japan |
PMID | 8254902
(Publication Type: Clinical Trial, English Abstract, Journal Article)
|
Chemical References |
- aspoxicillin
- Amoxicillin
- Ceftazidime
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Amoxicillin
(administration & dosage, analogs & derivatives)
- Bacterial Infections
(drug therapy, microbiology)
- Ceftazidime
(administration & dosage)
- Drug Therapy, Combination
(administration & dosage)
- Female
- Genital Diseases, Female
(drug therapy, microbiology)
- Humans
- Middle Aged
- Pregnancy
- Pregnancy Complications, Infectious
(drug therapy, microbiology)
|